WallStreetZenWallStreetZen

NASDAQ: PRTA
Prothena Corp Public Ltd Co Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for PRTA

Based on 5 analysts offering 12 month price targets for Prothena Corp Public Ltd Co.
Min Forecast
$60.00+17.65%
Avg Forecast
$88.40+73.33%
Max Forecast
$129.00+152.94%

Should I buy or sell PRTA stock?

Based on 5 analysts offering ratings for Prothena Corp Public Ltd Co.
Buy
Strong Buy
1 analysts 20%
Buy
3 analysts 60%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PRTA stock forecasts and price targets.

PRTA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Cantor Fitzgerald
Top 6%
95
Strong BuyReiterates$129.00+152.94%2023-08-22
HC Wainwright & Co.
Bottom 1%
1
BuyReiterates$90.00+76.47%2023-08-04
JMP Securities
Bottom 5%
5
BuyMaintains$83.00+62.75%2023-08-04
RBC Capital
Top 8%
93
HoldMaintains$60.00+17.65%2023-05-05
SVB Leerink
Bottom 44%
44
BuyInitiates Coverage On$80.00+56.86%2023-04-24

1 of 1

Forecast return on equity

Is PRTA forecast to generate an efficient return?
Company
N/A
Industry
0.91%
Market
28.82%

Forecast return on assets

Is PRTA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.07%

PRTA revenue growth forecast

How is PRTA forecast to perform vs Biotechnology companies and vs the US market?
Company
58.57%
Industry
35.95%
Market
8.15%
PRTA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PRTA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PRTA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PRTA$51.00$88.40+73.33%Buy
IMVT$20.39$28.46+39.55%Strong Buy
MDGL$153.34$279.00+81.95%Buy
RARE$36.43$93.00+155.28%Strong Buy
NTLA$32.39$77.58+139.53%Strong Buy
View Top Biotech Stocks

Prothena Public Co Stock Forecast FAQ

Is Prothena Public Co Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: PRTA) stock is to Buy PRTA stock.

Out of 5 analysts, 1 (20%) are recommending PRTA as a Strong Buy, 3 (60%) are recommending PRTA as a Buy, 1 (20%) are recommending PRTA as a Hold, 0 (0%) are recommending PRTA as a Sell, and 0 (0%) are recommending PRTA as a Strong Sell.

If you're new to stock investing, here's how to buy Prothena Public Co stock.

What is PRTA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: PRTA) forecast ROE is N/A, which is considered weak.

What is PRTA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year PRTA price target, the average PRTA price target is $88.40, with the highest PRTA stock price forecast at $129.00 and the lowest PRTA stock price forecast at $60.00.

On average, Wall Street analysts predict that Prothena Public Co's share price could reach $88.40 by Aug 22, 2024. The average Prothena Public Co stock price prediction forecasts a potential upside of 73.33% from the current PRTA share price of $51.00.

What is PRTA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: PRTA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.07%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.